What is Medra?
Medra is building the world's first end-to-end Physical AI Scientist platform designed to revolutionize the drug discovery lifecycle. The company operates at the intersection of advanced machine learning, robotic automation, and real-time data optimization. By creating a closed-loop system that continuously learns from experimental outcomes, Medra enables researchers to predict therapeutic success with unprecedented accuracy. This platform is engineered to replace traditional, fragmented research workflows with a unified, autonomous environment that scales across every stage of development, from initial target identification to preclinical validation.
How much funding has Medra raised?
Medra has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2025): $52M with participation from Menlo Ventures, Seven Seven Six, Catalio Capital Management, Human Capital, and Neo
Key Investors in Medra
Menlo Ventures
Menlo Ventures is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology companies across sectors such as enterprise software, consumer internet, fintech, infrastructure, and frontier tech.
Seven Seven Six
Seven Seven Six is an early-stage venture capital firm that focuses on innovation at the crossroads of product and people, utilizing a self-developed operating system named Cerebro to enhance team scalability and portfolio monitoring.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, with a specific focus on breakthrough biomedical technology companies.
What's next for Medra?
With the successful closure of this major strategic investment, Medra is poised to enter a phase of rapid operational expansion. The company intends to utilize the capital to enhance its robotic execution capabilities and broaden its reach within the global biotech ecosystem. As the firm matures, the focus will likely shift toward establishing high-value partnerships with major pharmaceutical entities, leveraging its AI-driven platform to reduce the cost and time associated with bringing new drugs to market. The strategic backing from top-tier venture firms provides not only the necessary liquidity but also the institutional expertise required to navigate the complex regulatory and technical landscapes of the healthcare industry.
See full Medra company page
